Key result
Anti-Kv1.4 antibodies were present in 10.8% of myasthenia gravis patients, with seropositive patients experiencing higher rates of abnormal ECGs (60%) and clinically suspected myocarditis (11.4% vs 0%).
Why the study?
Are anti-Kv1.4 antibodies associated with cardiac involvements in patients with myasthenia gravis?
Population
650 patients with autoimmune myasthenia gravis (MG)
Comparison
Presence of anti-Kv1.4 antibodies vs Absence of anti-Kv1.4 antibodies
Design
Cross-sectional
Authors
Loading...
Anti-Kv1.4 antibodies may flag cardiac risk in MG; hypothesis-generating and should not yet alter practice.
Observational (n=650)
Are anti-Kv1.4 antibodies associated with cardiac involvements in patients with myasthenia gravis?
Absolute Event Rate: 11.4% vs 0%
Anti-Kv1.4 antibodies serve as potential markers for serious cardiac involvements, including myocarditis and lethal arrhythmias, in patients with myasthenia gravis.
Suzuki et al. (2013) conducted an observational in Myasthenia gravis (n=650). Anti-Kv1.4 antibodies vs. Absence of anti-Kv1.4 antibodies was evaluated on Clinically suspected myocarditis. Anti-Kv1.4 antibodies were present in 10.8% of myasthenia gravis patients, with seropositive patients experiencing higher rates of abnormal ECGs (60%) and clinically suspected myocarditis (11.4% vs 0%).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: